National Research Corporation provides analytics and insights that facilitate measurement and enhancement of the patient and employee experience in the United States and Canada. More Details
Solid track record with adequate balance sheet.
Share Price & News
How has National Research's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: NRC is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: NRC's weekly volatility (5%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: NRC underperformed the US Healthcare industry which returned 12% over the past year.
Return vs Market: NRC underperformed the US Market which returned 19.7% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is National Research's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall StShould You Rely On National Research's (NASDAQ:NRC) Earnings Growth?
2 weeks ago | Simply Wall StNational Research (NASDAQ:NRC) Could Easily Take On More Debt
1 month ago | Simply Wall StIs Now The Time To Put National Research (NASDAQ:NRC) On Your Watchlist?
Is National Research undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: NRC ($53.45) is trading above our estimate of fair value ($17.31)
Significantly Below Fair Value: NRC is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: NRC is poor value based on its PE Ratio (35.5x) compared to the US Healthcare industry average (23.9x).
PE vs Market: NRC is poor value based on its PE Ratio (35.5x) compared to the US market (19.7x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate NRC's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: NRC is overvalued based on its PB Ratio (23.8x) compared to the US Healthcare industry average (3.2x).
How is National Research forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as National Research has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Check out National Research's track record over time to understand how much the company has returned to shareholders and its earnings growth rate in the past.
- Explore growth companies in the Healthcare industry.
How has National Research performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: NRC has high quality earnings.
Growing Profit Margin: NRC's current net profit margins (28.7%) are higher than last year (24.9%).
Past Earnings Growth Analysis
Earnings Trend: NRC's earnings have grown by 16% per year over the past 5 years.
Accelerating Growth: NRC's earnings growth over the past year (19.9%) exceeds its 5-year average (16% per year).
Earnings vs Industry: NRC earnings growth over the past year (19.9%) underperformed the Healthcare industry 22.6%.
Return on Equity
High ROE: NRC's Return on Equity (66.5%) is considered outstanding.
How is National Research's financial position?
Financial Position Analysis
Short Term Liabilities: NRC's short term assets ($47.4M) exceed its short term liabilities ($32.1M).
Long Term Liabilities: NRC's short term assets ($47.4M) exceed its long term liabilities ($38.4M).
Debt to Equity History and Analysis
Debt Level: NRC's debt to equity ratio (55.7%) is considered high.
Reducing Debt: NRC's debt to equity ratio has increased from 7.1% to 55.7% over the past 5 years.
Debt Coverage: NRC's debt is well covered by operating cash flow (115.1%).
Interest Coverage: NRC's interest payments on its debt are well covered by EBIT (22.9x coverage).
What is National Research current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate NRC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate NRC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if NRC's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if NRC's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: NRC is not paying a notable dividend for the US market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of NRC's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Mike Hays (65 yo)
Mr. Michael D. Hays, also known as Mike, serves as an Advisor of Picker Institute Inc. Mr. Hays founded National Research Corp. in 1981 and has been its Chief Executive Officer since 1981 and serves as its...
CEO Compensation Analysis
Compensation vs Market: Mike's total compensation ($USD233.88K) is below average for companies of similar size in the US market ($USD4.15M).
Compensation vs Earnings: Mike's compensation has been consistent with company performance over the past year.
|Lead Independent Director||8.5yrs||US$175.00k||0.11% |
|Independent Director||19.42yrs||US$150.00k||1.23% |
|Independent Director||5.08yrs||US$150.00k||no data|
Experienced Board: NRC's board of directors are seasoned and experienced ( 14 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: NRC insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
National Research Corporation's company bio, employee growth, exchange listings and data sources
- Name: National Research Corporation
- Ticker: NRC
- Exchange: NasdaqGS
- Founded: 1981
- Industry: Health Care Services
- Sector: Healthcare
- Market Cap: US$1.350b
- Shares outstanding: 25.26m
- Website: https://nrchealth.com
Number of Employees
- National Research Corporation
- 1245 Q Street
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|NRC||NasdaqGS (Nasdaq Global Select)||Yes||Common Stock||US||USD||May 2013|
|NR1A||BST (Boerse-Stuttgart)||Yes||Common Stock||DE||EUR||May 2013|
National Research Corporation provides analytics and insights that facilitate measurement and enhancement of the patient and employee experience in the United States and Canada. Its portfolio of subscripti...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/11/26 23:03|
|End of Day Share Price||2020/11/25 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.